Jazz Pharmaceuticals (JAZZ) Amortization - Intangibles (2010 - 2026)

Jazz Pharmaceuticals has reported Amortization - Intangibles for 17 years, with the latest figure at $172.3 million in Q1 2026.

• For the quarter ending Q1 2026, Amortization - Intangibles rose 11.59% year-over-year to $172.3 million; the trailing twelve-month figure through Mar 2026 stood at $672.5 million (up 7.43% YoY), and the FY2025 full-year result was $654.7 million, up 4.36% from the prior year.
• Amortization - Intangibles for Q1 2026 stood at $172.3 million, up from $169.7 million in the prior quarter.
• The five-year high for Amortization - Intangibles was $172.3 million in Q1 2026, with the low at $137.4 million in Q4 2022.
• Average Amortization - Intangibles over 5 years is $156.6 million, with a median of $155.2 million recorded in 2024.
• Year-over-year, Amortization - Intangibles jumped 152.37% in 2022 and decreased 12.96% in 2023.
• Tracing JAZZ's Amortization - Intangibles over 5 years: stood at $137.4 million in 2022, then gained by 10.31% to $151.6 million in 2023, then increased by 4.85% to $158.9 million in 2024, then rose by 6.82% to $169.7 million in 2025, then climbed by 1.51% to $172.3 million in 2026.
• The last three Amortization - Intangibles figures came in at $172.3 million (Q1 2026), $169.7 million (Q4 2025), and $168.4 million (Q3 2025), per Business Quant data.

Peer Comparison